myriad genetics glp-1 receptor agonist weight management diabetes treatments Schematic illustration of monoagonists, dual agonists and triple Advances in GLP-1 receptor agonists:

There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

Then feel stronger, more in control, and more consistent over 34 months of daily use.* SUPPORT APPETITE, ENERGY, AND MOTIVATION NATURALLY: Feel fuller longer without feeling forced

That rule is a heuristic, not a biological law